Ling M Wong1, Naomi J Goodrich-Hunsaker1, Yingratana McLennan1, Flora Tassone2, Melody Zhang3, Susan M Rivera4, Tony J Simon1. 1. Department of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center. 2. Department of Biochemistry and Molecular Medicine, University of California, Davis Medical Center. 3. Department of Neurobiology, Physiology, and Behavior, University of California, Davis. 4. Department of Psychology, University of California, Davis.
Abstract
OBJECTIVE: Fragile X premutation carriers (fXPCs) have an expansion of 55-200 CGG repeats in the FMR1 gene. Male fXPCs are at risk for developing a neurodegenerative motor disorder (FXTAS) often accompanied by inhibitory control impairments, even in fXPCs without motor symptoms. Inhibitory control impairments might precede, and thus indicate elevated risk for motor impairment associated with FXTAS. We tested whether inhibitory impairments are observable in fXPCs by assessing oculomotor performance. METHOD: Participants were males aged 18-48 years asymptomatic for FXTAS. FXPCs (n = 21) and healthy age-matched controls (n = 22) performed four oculomotor tasks. In a Fixation task, participants fixated on a central cross and maintained gaze position when a peripheral stimulus appeared. In a Pursuit task, participants maintained gaze on a square moving at constant velocity. In a Prosaccade task, participants fixated on a central cross, then looked at a peripheral stimulus. An Antisaccade task was identical to the Prosaccade task, except participants looked in the direction opposite the stimulus. Inhibitory cost was the difference in saccade latency between the Antisaccade and Prosaccade tasks. RESULTS: Relative to controls, fXPCs had longer saccade latency in the Antisaccade task. In fXPCs, inhibitory cost was positively associated with vermis area in lobules VI-VII. CONCLUSION: Antisaccades require inhibitory control to inhibit reflexive eye movements. We found that eye movements are sensitive to impaired inhibitory control in fXPCs asymptomatic for FXTAS. Thus, eye movements may be useful in assessing FXTAS risk or disease progression.
OBJECTIVE:Fragile X premutation carriers (fXPCs) have an expansion of 55-200 CGG repeats in the FMR1 gene. Male fXPCs are at risk for developing a neurodegenerative motor disorder (FXTAS) often accompanied by inhibitory control impairments, even in fXPCs without motor symptoms. Inhibitory control impairments might precede, and thus indicate elevated risk for motor impairment associated with FXTAS. We tested whether inhibitory impairments are observable in fXPCs by assessing oculomotor performance. METHOD:Participants were males aged 18-48 years asymptomatic for FXTAS. FXPCs (n = 21) and healthy age-matched controls (n = 22) performed four oculomotor tasks. In a Fixation task, participants fixated on a central cross and maintained gaze position when a peripheral stimulus appeared. In a Pursuit task, participants maintained gaze on a square moving at constant velocity. In a Prosaccade task, participants fixated on a central cross, then looked at a peripheral stimulus. An Antisaccade task was identical to the Prosaccade task, except participants looked in the direction opposite the stimulus. Inhibitory cost was the difference in saccade latency between the Antisaccade and Prosaccade tasks. RESULTS: Relative to controls, fXPCs had longer saccade latency in the Antisaccade task. In fXPCs, inhibitory cost was positively associated with vermis area in lobules VI-VII. CONCLUSION: Antisaccades require inhibitory control to inhibit reflexive eye movements. We found that eye movements are sensitive to impaired inhibitory control in fXPCs asymptomatic for FXTAS. Thus, eye movements may be useful in assessing FXTAS risk or disease progression.
Authors: David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-11-05 Impact factor: 3.568
Authors: Caroline J Moore; Eileen M Daly; Flora Tassone; Carolyn Tysoe; Nicole Schmitz; Virginia Ng; Xavier Chitnis; Philip McGuire; John Suckling; Kay E Davies; Randi J Hagerman; Paul J Hagerman; Kieran C Murphy; Declan G M Murphy Journal: Brain Date: 2004-10-13 Impact factor: 13.501
Authors: Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet A Date: 2008-04-15 Impact factor: 2.802
Authors: Cary S Kogan; Jeremy Turk; Randi J Hagerman; Kim M Cornish Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-09-05 Impact factor: 3.568
Authors: Yingratana A McLennan; Matthew W Mosconi; Forrest J McKenzie; Jessica Famula; Bennet Krawchuk; Kyoungmi Kim; Courtney J Clark; David Hessl; Susan M Rivera; Tony J Simon; Flora Tassone; Randi J Hagerman Journal: Mov Disord Clin Pract Date: 2022-04-28